First Zantac cancer risk trial in California postponed by months
Send a link to a friend
[February 24, 2023]
By Brendan Pierson
(Reuters) - The first scheduled trial over claims that GSK Plc's
heartburn drug Zantac caused cancer, which had been set to begin Monday,
has been postponed, likely by several months.
The case, brought by California resident James Goetz in Alameda County
Superior Court, is now expected to go to trial in June or July, though
no date has yet been set, spokespersons for GSK and Goetz's attorneys
said on Thursday.
Goetz alleges he developed bladder cancer from taking Zantac, and his
case will offer an early test of how Zantac cancer claims may fare in
state courts.
A federal judge in December threw out all of the Zantac cases in federal
court, some 50,000, after finding the opinions of the plaintiffs' expert
witnesses linking Zantac to cancer were not backed by sound science.
Tens of thousands of cases still remain in state courts, many
consolidated before Judge Evelio Grillo in Alameda. Grillo is currently
considering what expert testimony to allow in Goetz's trial.
Zantac, first approved by the U.S. Food & Drug Administration in 1983,
became the world's best selling medicine in 1988 and one of the first
drugs to top $1 billion in annual sales.
![](http://archives.lincolndailynews.com/2023/Feb/24/images/ads/current/charrons_bch_2022.png)
[to top of second column]
|
![](../images/022423PIX/health55.jpg)
Zantac heartburn pills are seen in this
picture illustration taken October 1, 2019. REUTERS/Brendan McDermid/Illustration
![](http://archives.lincolndailynews.com/2023/Feb/24/images/ads/current/napa_lda_FILTERSALE_2023.png) Originally marketed by a forerunner
of GSK, it was later sold successively to Pfizer Inc, Boehringer
Ingelheim and finally Sanofi SA. All four drugmakers are facing
Zantac lawsuits and have denied the pill causes cancer.
In 2019, some manufacturers and pharmacies halted sales of the drug
over concerns that its active ingredient, ranitidine, degraded over
time to form a chemical called NDMA. While NDMA is found in low
levels in food and water, it is known to cause cancer in larger
amounts.
The FDA in 2020 pulled all remaining brand name Zantac and generic
versions off the market, triggering a wave of lawsuits.
(Reporting by Brendan Pierson in New York, Editing by Alexia
Garamfalvi and Lincoln Feast)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |